RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs

Infection, Genetics and Evolution

Volumn 14, Issue 1, 2013, Pages 247-257

  Waheed, Yasir ^a   Bhatti, Attya ^a   Ashraf, Muhammad ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Genotypes; Hepatitis C virus; Inhibitors; Polymerase; Replication

Indexed keywords

4' AZIDOCYTIDINE; ABT 333; ANTIVIRUS AGENT; BALAPIRAVIR; BI 207127; BILB 1941; BOCEPREVIR; FILIBUVIR; IDX 184; INTERFERON; LOMIBUVIR; MERICITABINE; MK 0608; MK 3281; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VCH 759; VCH 916;

ANEMIA; ANTIVIRAL ACTIVITY; DRUG BINDING SITE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RNA SYNTHESIS; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; RNA REPLICASE;

EID: 84873167874     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.12.004     Document Type: Review

References (141)

1. Abravanel F.L., Nicot F., Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs 2010, 19:963-975.
2. Ahmad N., Asgher M., Shafique M., Qureshi J.A. An evidence of high prevalence of hepatitis C virus in Faisalabad, Pakistan. Saudi Med. J. 2007, 28:390-395.
3. Anderson J.P., Daifuku R., Loeb L.A. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 2004, 58:183-205.
4. Aziz H., Ather M.A., Murtaza S., Irafan J., Waheed Y., Bilal I., Raza A. Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. Chin. Med. J. 2011, 124(9):1333-1337.
5. Aziz H., Gil M.L., Waheed Y., Adeeb U., Raza A., Bilal I., Ather M.A. Evaluation of prognostic factors for Peg interferon alfa-2b plus ribavirin treatment of HCV infected patients in Pakistan. Infect. Genet. Evol. 2011, 11:640-645.
6. Aziz, H., Raza, A., Waheed, Y., Gill, U., Gill, M.L., 2012. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alpha 2a plus ribavirin in hepatitis C virus genotype 3 infected patients. Int. J. Infect. Dis. http://dx.doi.org/10.1016/j.ijid.2012.03.012.
7. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81:1631-1648.
8. Bassit L., Grier J., Bennett M., Schinazi R.F. Combinations of 2¢-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir. Chem. Chemother. 2008, 19:25-31.
9. Behrens S.E., Tomei L., De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 1996, 15:12-22.
10. Bilello, J.P., Colla, M.L., Serra, I., Gillum, J.M., Soubasakos, M.A., Chapron, C., Li, B., Bonin, A., Panzo, R.J., Seifer, M., Standring, D.N. (downloaded july 2012) Enhance antiviral activity of IDX375, a novel HCV non-nucleoside inhibitor, in combination with other HCV antiviral agents in the genotype 1b replicon in vitro. Indenix Pharma, USA. pp. 192. <>. http://www.novirio.com/hcv/HCV2009%20IDX375.pdf.
11. Biswal B.K., Cherney M.M., Wang M., Chan L., Yannopoulos C.G., Bilimoria D., Nicolas O., Bedard J., James M.N. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 2005, 280:18202-18210.
12. Brainard D.M., Anderson M.S., Petry A.S., Dyck K.V., DeLepeleire I., Sneddon K., Cummings C.E., Nachbar R.B., Barnard R.J.O., Sun P., Panorchan P., Udezue E., Sanderson B., Wagner F., Iwamoto M., Chodakewitz J.A., Wangner J.A. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281 in genotype 1 and 3 HCV-infected patients. Hepatology 2009, 50:1026A.
13. Brass V., Gouttenoire J., Wahl A., Pal Z., Blum H.E., Penin F., Moradpour D. Hepatitis C virus RNA replication requires a conserved structural motif within the transmembrane domain of the NS5B RNA-dependent RNA polymerase. J. Virol. 2010, 84:11580-11584.
14. Bressanelli S., Tomei L., Roussel A. Crystal structure of the RNA dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. 1999, 96:13034-13039.
15. Bressanelli S., Tomei L., Rey F.A., De-Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 2002, 76:3482-3492.
16. Bruijne J., Rooij W.D., Vliet A.A.V., Zhou X.J., Temam M.F., Molles J., Chen J., Pietropaolo K., Sullivan-Bolyai J.Z., Mayers D., Reesin H.W. First in human pharmacokinetics and antiviral activity of IDX375, a novel non nucleoside hepatitis c virus polymerase inhibitor. Antimicrob. Agents Chemother. 2012, 10.1128/AAC.00451-12.
17. Butt S., Idrees M., Rehman I.U., Akbar H., Shahid M., Afzal S., Younas S., Amin I. Mixed genotype infections with hepatitis C virus, Pakistan. Emerg. Infect. Dis. 2011, 17:1565-1567.
18. Cameron C., Gotte M., Raney K.D. Viral Genome Replication 2009, Springer, New York.
19. Carrere-Kremer S., Montpellier-Pala C., Cocquerel L., Wychowski C., Penin F., Dubuisson J. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J. Virol. 2002, 76:3720-3730.
20. Carroll S.S., Tomassini J.E., Bosserman M., Getty K., Stahlhut M.W., Eldrup A.B., Bhat B., Hall D., Simcoe A.L., LaFemina R., Rutkowski C.A., Wolanski B., Yang Z., Migliaccio G., De Francesco R., Kuo L.C., MacCoss M., Olsen D.B. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J. Biol. Chem. 2003, 278:11979-11984.
21. Carroll S.S., Ludmerer S., Handt L., Koeplinger K., Zhang N.R., Graham D., Davies M.E., MacCoss M., Hazuda D., Olsen D.B. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 2009, 53:926-934.
22. Chatterji U., Bobardt M., Selvarajah S., Yang F., Tang H., Sakamoto N., Vuagniaux G., Parkinson T., Gallay P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 2009, 284:16998-17005.
23. Chinnaswamy S., Yarbrough I., Palaninathan S., et al. A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase. J. Biol. Chem. 2008, 283:20535-20546.
24. Chinnaswamy S., Cai H., Kao C.C. An update on small molecule inhibitors of the HCV NS5B polymerase: effect on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies. Virus Adapt. Treat. 2010, 2:73-89.
25. Chinnaswamy S., Murali A., Cai H., Yi G., Palaninathan S., Kao C.C. Conformations of the monomeric hepatitis C virus RNA dependent RNA polymerase. Virus Adapt. Treat. 2010, 2:21-39.
26. Chinnaswamy S., Murali A., Li P., Fujisaki K., Kao C.C. Regulation of de novo-initiated RNA synthesis in hepatitis C virus RNA-dependent RNA polymerase by intermolecular interactions. J. Virol. 2010, 84:5923-5935.
27. Chou A.H., Tsai H.F., Wu Y.Y., Hu C.Y., Hwang L.H., Hsu P.I., Hsu P.N. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J. Immunol. 2005, 174:2160-2166.
28. Cooper C., Lawitz E.J., Ghali P., Rodriguez-Torres M., Anderson F.H., Lee S.S., Bedard J., Chauret N., Thibert R., Boivin I., Nicolas O., Proulx L. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol. 2009, 51:39-46.
29. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. 2001, 98:6895-6900.
30. DeFrancesco R. Robust antiviral efficacy of a " finger-loop" allosteric inhibitor of the HCV polymerase in HCV infected chimpanzees. Global Antiviral J. 2007, 3:25.
31. Deval J., Powdrill M.H., D'Abramo C.M., Cellai L., Gotte M. Pyrophosphorylytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 2007, 51:2920-2928.
32. Duffy S., Shackelton L.A., Holmes E.C. Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 2008, 9:267-276.
33. Dutartre H., Bussetta C., Boretto J., Canard B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues. Antimicrob. Agents Chemother. 2006, 50:4161-4169.
34. Erhardt A., Deterding K., Benhamou Y., Reiser M., Forns X., Pol S., Calleja J.L., Ross S., Spangenberg H.C., Garcia S.J., Fuchs M., Enriquez J., Wiegard J., Stern J., Wu K., Kukolj G., Marquis M., Beaulieu P., Nehmiz G., Steffgen J. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir. Ther. 2009, 14:23-32.
35. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
36. Ferrari E., Wright-Minogue J., Fang J.W., Baroudy B.M., Lau J.Y., Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 1999, 73:1649-1654.
37. Gallois-Montbrun S., Chen Y., Dutartre H., Sophys M., Morera S., Guerreiro C., Schneider B., Mulard L., Janin J., Veron M., Deville-Bonne D., Canard B. Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets. Mol. Pharmacol. 2003, 63:538-546.
38. Gane E.J., Rodriguez-Torres M., Nelson D.E., Jacobson I.M., Duca A., Hyland R., Hill G., Albanis E., Symonds W.T., Berrey M.M. Sustained virologic response (SVR) following RG7128 1500mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J. Hepatol. 2010, 52(Suppl. 1):S16.
39. Gane E.J., Bisceglie A.M.D., Sulkowski M.S., Jacobson I.M., Alves K., Koziel M.J., DeSouza C., Kieffer T.L., Kauffman R.S., Nelson D.R. Vertex QUAD therapy yielded 83-93% SVR with 12 weeks duration of therapy: VX222/Telaprevir in combination with peginterferon alpha 2a and ribavirin in treatment naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR 12 interim analysis. APASL 2012, 22.
40. Gane E., Stedman C., Hyland R., Sorenson R., Symonds W., Hindes R., Berrey M. Once daily GS-7977 plus ribavirin in HCV genotypes 1-3: the electron trial. EASL 2012, 47:1113.
41. Goto K., Watashi K., Murata T., Hishiki T., Hijikata M., Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A and NIM811. Biochem. Biophys. Res. Commun. 2006, 343:879-884.
42. Gray F., Amphlett E., Bright H., Chambers L., Cheasty A., Fenwick R., Haigh D., Hartley D., Howes P., Jarvest R., Mirzai F., Nerozzi F., Parry N., Slater M., Smith S., Thommes P., Wilkinson C., Williams E. GSK625433: a novel and highly potent inhibitor of the HCV NS5B polymerase. J. Hepatol. 2007, 46:S225.
43. Guedj J., Dahari H., Shudo E., Smith P., Perseson A.S. Hepatitis c viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012, 55:1030-1037.
44. Hang J.Q., Yang Y., Harris S.F., Leveque V., Whittington H.J., Rajyaguru S., Ao-Ieong G., McCown M.F., Wong A., Giannetti A.M., Le Pogam S., Talamas F., Cammack N., Najera I., Klumpp K. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J. Biol. Chem. 2009, 284:15517-15529.
45. Hebner C.M., Han B., Brendza K.M., Nash M., Sulfab M., Tian Y., Hung M., Fung W., Vivian R.W., Trenkle J., Taylor J., Bjornson K., Bonday S., Liu X., Link J., Neyts J., Sakowicz R., Zhong W., Tang H., Schmitz U. The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLOS One 2012, 7:e39163.
46. Herrmann E., Neumann A.U., Schmidt J.M., Zeuzem S. Hepatitis C virus kinetics. Antivir. Ther. 2000, 5:85-90.
47. Hijikata M., Shimizu Y.K., Kato H., Iwamoto A., Shih J.W., Alter H.J., Purcell R.H., Yoshikura H. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J. Virol. 1993, 67:1953-1958.
48. Hong Z., Cameron C.E., Walker M.P., Castro C., Yao N., Lau J.Y., Zhong W. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 2001, 285:6-11.
49. Hopkin S., Scorneaux B., Huang Z., Murray M.G., Wring S., Smitley C., Harris R., Erdmann F., Fischer G., Ribeill Y. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 2009, 54:660-672.
50. Howe A.Y., Cheng H., Johann S., Mullen S., Chunduru S.K., Young D.C., Bard J., Chopra R., Krishnamurthy G., Mansour T., O'Connell J. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 2008, 52:3327-3338.
51. Idrees M., Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect. Dis. 2008, 8:69.
52. Index Pharma. Downloaded 6th July, 2012. Drug discovery and development: IDX 184, a nucleoside/tide polymerase inhibitor. <>. http://www.idenix.com/hcv/drug.html.
53. Kao C.C., Yang X., Kline A., Wang Q.M., Barket D., Heinz B.A. Template requirements for RNA synthesis by a recombinant hepatitis C virus RNA dependent RNA polymerase. J. Virol. 2000, 74:11121-11128.
54. Kao C.C., Fan B., Chinnaswamy S., Cai H., Ranjith-Kumar C.T., Deval J. Assays for RNA synthesis and replication by the hepatitis C virus. Front. Biol. 2012, 10.1007/s11515-012-1188-0.
55. Klumpp K., Leveque V., Le Pogam S., Ma H., Jiang W.R., Kang H., Granycome C., Singer M., Laxton C., Hang J.Q., Sarma K., Smith D.B., Heindl D., Hobbs C.J., Merrett J.H., Symons J., Cammack N., Devos J.A., Martin R., Najera I. The novel nucleoside analog. R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 2006, 281:3793-3799.
56. Klumpp K., Leveque V., Le Pogam S., Ma H., Jiang W.R., Kang H., Granycome C., Singer, Kneteman N.M., Howe A.Y., Gao T., Lewis J., Pevear D., Lund G., Douglas D., Mercer D.F., Tyrrell D.F., Immermann F., Chaudhary I., Speth J., Villano S.A., O'Connell J., Collett M. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009, 49:745-752.
57. Kneteman N.M., Howe A.Y., Gao T. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009, 49:745-752.
58. Kukolj G., McGibbon G.A., McKercher G., Marquis M., Lefebvre S., Thauvette L., Gauthier J., Goulet S., Poupart M.A., Beaulieu P.L. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 2005, 280:39260-39267.
59. Kukolj G., Anderson P.C., Boes M., Cordingely M.G., Coulombe R., Garneau M., Gillard J., Goulet S., Jolicoeur E., Lagace L., Lamarre D., Laplante S., Marquis M., Mckercher G., Pellerin C., Poupart M.A., Beaulieu P.L. Preclinical characterization of hepatitis C virus NS5B polymerase non-nucleosdie inhibitor BILB 1941. EASL 2011, 48:08d.
60. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Young S.K., Lee B., Heckerman D., Carlson J., Reyor L.L., Kleyman M., McMahon C.M., Birch C., Schulze Zur Wiesch J., Ledlie T., Koehrsen M., Kodira C., Roberts A.D., Lauer G.M., Rosen H.R., Bihl F., Cerny A., Spengler U., Liu Z., Kim A.Y., Xing Y., Schneidewind A., Madey M.A., Fleckenstein J.F., Park V.M., Galagan J.E., Nusbaum C., Walker B.D., Lake-Bakaar G.V., Daar E.S., Jacobson I.M., Gomperts E.D., Edlin B.R., Donfield S.M., Chung R.T., Talal A.H., Marion T., Birren B.W., Henn M.R., Allen T.M. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769-1778.
61. Lalezari J., Gane E., Rodriguez-Torres M. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days. J. Hepatol. 2008, 48(Suppl. 2):S29.
62. Lalezari J., Azmuth D., Casiró A., Vargas H.E., Dubuc Patrick G., Lius W., Pietropaolo K., Zhou X., Sullivan-Bólyai J., Mayer D.L. Antiviral activity, safety and pharmacokinetics of IDX184, a liver targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology 2009, 50:228A.
63. Lallos L., La Cola M., Serra I., Bilello J.P., Soubasakos M.A., Li A., Panzo R.J., Gillum J.M., Bonin A., Siefer M., Standring D.N. Combination of IDX184, a nucleotide prodrug polymerase inhibitor, with other classes of HCV inhibitors is additive to synergistic in the HCV replicon in vitro. Hepatology 2009, 50:1045A.
64. Larrey D., Benhamou Y., Lohse A.W. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology 2009, 50:1044A.
65. Larrey D., Lohse A.W., Ledinghen V.D., Trepo C., Gerlach T., Zarski J.P., Tran A., Mathurin P., Thimme R., Arasteh K., Trautwein C., Cerny A., Dikopoulos N., Schuchmann M., Heim M.H., Gerken G., Stern J.O., Wu K., Abdallah N., Girlich B., Scherer J., Berger F., Marquis M., Kukolj G., Bocher W., Steffgen J. Rapid and strong antiviral activity of the non-nucleoside NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 3a and ribavirin. J. Hepatol. 2012, 57:39-46.
66. Laurila M.R., Makeyev E.V., Bamford D.H. Bacteriophage phi 6 RNA-dependent RNA polymerase: molecular details of initiating nucleic acid synthesis without primer. J. Biol. Chem. 2002, 277:17117-17124.
67. Lavie A., Konrad M. Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase. Med. Chem. 2004, 4:351-359.
68. Lawitz E., Cooper C., Rodriguez-Torres M. Tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype-1 infection. J. Hepatol. 2009, 50:S37.
69. Lawitz E., Rodrigues-Torres M., DeMicco T. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J. Hepatol. 2009, 50:S384.
70. Le Pogam S., Kang H., Harris S.F., Leveque V., Giannetti A.M., Ali S., Jiang W.R., Rajyaguru S., Tavares G., Oshiro C., Hendricks T., Klumpp K., Symons J., Browner M.F., Cammack N., Najera I. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 2006, 80:6146-6154.
71. Le Pogam S., Chhabra M., Ali S., Yan J., Ilnicka M.J., Kang H., Wong J.M., Kosaka A., Ewing A., Seshaadri A., De La Rosas A., Bradford W.Z., Klumpp K., Shulman N., Smith P.F., Cammack N., Najera I. Combination therapy with nucleoside polymerase R7128 and protease R7227/ITMN-191 inhibitors in genotype 1 HCV infected patients: interim resistance analysis of INFORM-1 cohorts A-D. Hepatology 2009, 50:1037A.
72. Legrand-Abravanel F., Nicot F., Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs 2010, 19:963-975.
73. Levin J. Safety and Tolerability of Filibuvir, a Non-nucleoside Inhibitor of HCV Polymerase 2009, Conference Reports for NTAP, HepDART, Hawaii.
74. Lindenbach B.D., Meuleman P., Ploss A., Vanwolleghem T., Syder A.J., McKeating J.A., Lanford R.E., Feinstone S.M., Major M.E., Leroux-Roels G., Rice C.M. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vivo. Proc. Natl. Acad. Sci. USA 2006, 103:3805-3809.
75. Liu Z., Yang F., Robotham J.M., Tang H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 2009, 83:6554-6565.
76. Lohmann V., Körner F., Herian U., Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 1997, 71:8416-8428.
77. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
78. Lohmann V., Overton H., Bartenschlager R. Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. J. Biol. Chem. 1999, 274:10807-10815.
79. Lu L., Mo H., Pilot-Matias T.J., Molla A. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759. Antimicrob. Agents Chemother. 2007, 51:1889-1896.
80. Luo G., Hamatake R.K., Mathis D.M. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J. Virol. 2000, 74:851-863.
81. Ma, H., Inocencio, N., Cruz, J.E., Cammack, N., Klumpp, K., 2009. Incorporation and chain termination efficiencies can differ between nucleoside inhibitors of HCV replication at initiation and elongation phases: identification of a potential additional mechanism of action of R1479-TP. In: Presented at the 16th International Symposium on Hepatitis C Virus and Related Viruses, 2009, Nice, France.
82. Magee W.C., Aldern K.A., Hostetler K.Y., Evans D.H. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 2008, 52:586-597.
83. Mansky L.M., Bernard L.C. 3'-azido-3'- deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1. J. Virol. 2000, 74:9532-9539.
84. McCown M.F., Rajyaguru S., Le Pogam S., Ali S., Jiang W.R., Kang H., Symons J., Cammack N., Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52:1604-1612.
85. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., McNair L., Alam J., Muir A.J. Telaprevie with peginterferon and ribavirin for chronic HCV genotpe 1 infection. N. Eng. J. Med. 2009, 360:1827-1838.
86. Narjes F., Crescenzi B., Ferrara M., Habermann J., Colarusso S., Ferreira M.R.R., Stansfield I., Mackay A.C., Conte I., Ercolani C., Zaramella S., Palumbi M., Meuleman P., Roels G.L., Giuliana C., Firoe F., Marco S.D., Baiocco P., Koch U., Migliaccia G., Altamura S., Laufer R., Francesco R.D., Rowley M. Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino) ethyl] amino}-7,8-dihydro-6H-indolo [1,2-e][1,5] benzoxazocine-11- carboxylic acid (MK-3281), a potent and orally bioavailable finger loop inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem. 2010, 54:289-301.
87. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Ladyen T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
88. Nielsen S.U., Bassendine M.F., Burt A.D., Bevitt D.J., Toms G.L. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J. Gen. Virol. 2004, 85:1497-1507.
89. Oh J.W., Ito T., Lai M.M. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. J. Virol. 1999, 73:7694-7702.
90. Ohara E., Hiraqa N., Imamura M., Iwao E., Kamiya N., Yamada I., Kono T., Onishi M., Hirata, Mitsui F., Kawaoka T., Tsuqe M., Takahashi S., Abe H., Hayes C.N., Ochi H., Tateno C., Yoshizato K., Tanaka S., Chayama K. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice 2011, 54(7):872-878.
91. O'Reilly E.K., Kao C.C. Analysis of RNA-Dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology 1998, 252:287-303.
92. Pawlotsky J.M. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin. Liver Dis. 2003, 7:45-66.
93. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
94. Pierra C., Benzaria S., Amador A., Moussa A., Mathieu S., Storer R., Gosselin G. Nm 283, an efficient prodrug of the potent anti-HCV agent 2¢-C-methylcytidine. Nucleos. Nucleot. Nucleic Acids 2005, 24:767-770.
95. Pockros P.J., Nelson D., Godofsky E., Rodriguez-Torres M., Everson G.T., Fried M.W., Ghalib R., Harrison S., Nyberg L., Shiffman M.L., Najera I., Chan A., Hill G. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48:385-397.
96. Poijarvi-Virta P. Prodrug approaches of nucleotides and oligonucleotides. Curr. Med. Chem. 2006, 13:3441-3465.
97. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy R.K., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J. Boceprevir for untreated chronic HCV genotype 1 Infection. N. Eng. J. Med. 2011, 364:1196-1206.
98. Poordad F., Lawitz E., DeJesus E., Kowdley K., Gaultier I., Cohen D., Xie W., Larsen L., Pilot-Matias T., Koev G., Dumas E., Podsadecki T., Bernstein B. ABT-072 or ABT-333 combined with Pegylated Interferon/Ribavirin after 3 day monotherapy in HCV genotype 1 infected treatment naïve subjects: 12 weeks sustained virological response (SVR) and safety results. EASL 2012, 47.
99. Powdrill M.H., Bernatchez J.A., Gotte M. Inhibitors of the Hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2010, 2:2169-2195.
100. Ranjith-Kumar C.T., Kao C.C. Biochemical Activities of the HCV NS5B RNA Dependent RNA Polymerase. Hepatitis C Viruses: Genomes and Molecular Biology 2006, 293-310. Horizon Bioscience, United Kingdom. S. Tan (Ed.).
101. Ranjith-Kumar C.T., Kao C.C. Recombinant viral RdRps can initiate RNA synthesis from circular templates. RNA 2006, 12:303-312.
102. Ranjith-Kumar C.T., Gajewski J., Gutshall L., Maley D., Sarisky R.T., Kao C.C. Terminal nucleotidyl transferase activity of recombinant Flaviviridae RNA-dependent RNA polymerases: implication for viral RNA synthesis. J. Virol. 2001, 75:8615-8623.
103. Ranjith-Kumar C.T., Gutshall L., Kim M.J., Sarisky R.T., Kao C.C. Requirements for de novo initiation of RNA synthesis by recombinant flaviviral RNA-dependent RNA polymerases. J. Virol. 2002, 76:12526-12536.
104. Ranjith-Kumar C.T., Wen Y., Baxter N., Bhardwaj K., Kao C.C. A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A. PLoS ONE 2011, 6:e22575.
105. Reed K.E., Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 1999, 242:55-84.
106. Roberts S.K., Cooksley G., Dore G.J., Robson R., Shaw D., Berns H., Hill G., Klumpp K., Najera I., Washington C. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008, 48:398-406.
107. Rodrigues-Torres M., Lawitz E., Cohen D. Treatment naive, HCV genotype 1-infected subjects show significantly greater decrease when treated for 28 days of ABT-333 plus peginterferon and ribavirin than peginterferon and ribavirin alone. Hepatology 2009, 50:5A.
108. Rodriguez-Torres M., Lawitz E., Conway B. Safety and antiviral activity of the non-nucleoside polymerase inhibitor VX-222 in treatment naïve genotype 1 HCV infected patients. J. Hepatol. 2010, 52:S14.
109. Rong L., Dahari H., Ribeiro R.M., Perelson A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Trans. Med. 2010, 2:30-32.
110. Rubach J.K., Wasik B.R., Rupp J.C., Kuhn R.J., Hardy R.W., Smith J.L. Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro. Virology 2009, 384:201-208.
111. Safi S.Z., Badshah Y., Waheed Y., Fatima K., Tahir S., Shinwari A., Qadri I. Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan. Asian Biomed. 2010, 4:253-262.
112. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2009, 138:447-462.
113. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
114. Shi S.T., Herlihy K.J., Graham J.P., Nonomiya J., Rahavendran S.V., Skor H., Irvine R., Binford S., Tatlock J., Li H., Gonzalez J., Linton A., Patick A.K., Lewis C. Preclinical characterization of PF- 00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 2009, 53:2544-2552.
115. Shih I., Vliegen I., Peng B., Yang H., Paeshuyse J., Purstinger G., Fenaux M., Mabery E., Bahador G., Lehman L.S., Bondy S., Tse W., Reiser H., Lee W.A., Neyts J., Zhong W. Mechanistic characterization of GS-9190, a novel non nucleoside inhibitor of the hcv NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology 2007, 46:859A.
116. Simister P., Schmitt M., Geitmann M. Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. J. Virol. 2009, 83:11926-11939.
117. Sun X.L., Johnson R.B., Hockman M.A., Wang Q.M. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase. Biochem. Biophys. Res. Commun. 2000, 268:798-803.
118. Tariq H., Manzoor S., Parvaiz F., Javed F., Fatima K., Qadri I. An overview: in vitro models of HCV replication in different cell cultures. Infect. Genet. Evol. 2011, 12:13-20.
119. Tchesnokov E.P., Obikhod A., Schinazi R.F., Gotte M. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J. Biol. Chem. 2008, 283:34218-34228.
120. Tomei L., Altamura S., Bartholomew L., Bisbocci M., Bailey C., Bosserman M., Cellucci A., Forte E., Incitti I., Orsatti L., Koch U., De Francesco R., Olsen D.B., Carroll S.S., Migliaccio G. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 2004, 78:938-946.
121. Tomei L., Altamura S., Paenessa G., Francesco R., Migliaccio G. HCV antiviral resistance. The impact of in vitro studies on the development of anitiviral agents targeting the viral NS5B polymerase. Antiviral Chem. Chemother. 2005, 16:225-245.
122. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell Biochem. 1994, 140:1-22.
123. Troke P.J., Lweis P., Simpson P., Gore K., Hammond J., Craig C., Westby M. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus infected patients. Antimicrob. Agents Chemother. 2012, 56:1331-1341.
124. Vertex Pharma., 2012. Vertex announces 12week on treatment data and SCR4 from phase 2 study of interferon free treatment regimen of INCIVEK, VX 222 and ribavirin in people with Genotype 1 hepatitis C. (accessed 16.07.12), <>. http://www.investors.vrtx.com/releasedetail.cfm?releaseid=650944.
125. Villano S.A., Raible D., Harper D. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alpha-2b in tratment naive patients with chronic HCV. J. Hepatol. 2007, 56:S24.
126. Vliegen I., Paeshuyse J., Marbery E. GS-9190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants. Hepatology 2007, 46:855A.
127. Wagner R., Maring C., Donner P., Randolph A.C., Krueger T.W., Rockway J.K., Pratt, Liu D., Tufano M., Kati W.M., Liu Y., Lim H.B., Beyer J.M., Mondal R., Reisch R.J., Krishnan P., Beno D.W.A., Lau Y.Y., Shen J., Fishcer J.S., Goa Y., Molla A. Preclinical characterization of ABT-072: a novel non-nucleoside HCV polymerase inhibitor. J. Hepatol. 2009, 50:S352.
128. Waheed Y., Shafi T., Safi S.Z., Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J. Gasteroenterol. 2009, 15:5647-5653.
129. Waheed Y., Saeed U., Tahir S., Afzal M.S. Development of global consensus sequence and analysis of highly conserved domains of HCV NS5B protein. Hepat. Mon. 2012, 12(9):e6142. 10.5812/hepatmon.6142.
130. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Kräusslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
131. Wang Q.M., Hockman M.A., Staschke K., Johnson R.B., Case K.A., Lu J., Parsons S., Zhang F., Rathnachalam R., Kirkegaard K., Colacino J.M. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 2002, 76:3865-3872.
132. Watashi K., Ishii N., Hijikata M., Inoue D., Murata T., Miyanari Y., Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell. 2005, 19:111-122.
133. Wong K.A., Xu S., Martin R., Miller M.D., Mo H. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a and 6a. Virology 2012, 429:57-62.
134. Yamashita T., Kaneko S., Shirota Y., Qin W., Nomura T., Kobayashi K., et al. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J. Biol. Chem. 1998, 273:15479-15486.
135. Yan Y., Li Y., Munshi S., Sardana V., Cole J.L., Sardana M., Steinkuehler C., Tomei L., De Francesco R., Kuo L.C., Chen Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 1998, 7:837-847.
136. Yi G., Deval J., Fan B., Cai H., Soulard C., Ranjith-Kumar C.T., Smith D.B., Blatt L., Beigelman L., Kao C.C. Biochemical study of the comparative inhibition of Hepatitis C virus RNA polymerase by VX-222 and Filibuvir. Antimicrob. Agents Chemother. 2012, 56:830-837.
137. Young K.C., Lindsay K.L., Lee K.J., Liu W.C., He J.W., Milstein S.L., Lai M.M. Identification of a ribavirin resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003, 38:869-878.
138. Zennou V., Lam A.M., Keilman M., Steuer M., Espiritu C., Sofia M.J., Reddy P.G., Chang W., Rachakonda S., Otto M.J., Furman P.S. Combination of two complementary nucletide analogues PSI-7977 and PSI-938 effectively clears wild type and NS5B S282T HCV replicons comparison with combination of other antiviral compounds. J. Hepatol. 2010, 52:S400-S401.
139. Zeuzem S., Buggisch P., Agarwal K., Marcellin P., Sereni D., Klinker H., Moreno C., Zarski J.P., Horsmans Y., Mo H., Arterburn S., Knox S., Oldach D., McHutchison J.G., Manns M.P., Foster G.R. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Heptology 2012, 55:749-758.
140. Zhong W., Uss A.S., Ferrari E., Lau J.Y., Hong Z. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J. Virol. 2000, 74:2017-2022.
141. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:9294-9299.